Katja Michael to Leishmaniasis, Cutaneous
This is a "connection" page, showing publications Katja Michael has written about Leishmaniasis, Cutaneous.
Connection Strength
1.452
-
Montoya AL, Gil ER, Vinales I, Estevao IL, Taboada P, Torrico MC, Torrico F, Marco JD, Almeida IC, Michael K. Big is not better: Comparing two alpha-Gal-bearing glycotopes in neoglycoproteins as biomarkers for Leishmania (Viannia) braziliensis infection. Carbohydr Res. 2024 Feb; 536:109015.
Score: 0.928
-
Viana SM, Montoya AL, Carvalho AM, de Mendon?a BS, Portillo S, Olivas JJ, Karimi NH, Estevao IL, Ortega-Rodriguez U, Carvalho EM, Dutra WO, Maldonaldo RA, Michael K, de Oliveira CI, Almeida IC. Serodiagnosis and therapeutic monitoring of New-World tegumentary leishmaniasis using synthetic type-2 glycoinositolphospholipid-based neoglycoproteins. Emerg Microbes Infect. 2022 Dec; 11(1):2147-2159.
Score: 0.215
-
Subramaniam KS, Austin V, Schocker NS, Montoya AL, Anderson MS, Ashmus RA, Mesri M, Al-Salem W, Almeida IC, Michael K, Acosta-Serrano A. Anti-a-Gal antibodies detected by novel neoglycoproteins as a diagnostic tool for Old World cutaneous leishmaniasis caused by Leishmania major. Parasitology. 2018 11; 145(13):1758-1764.
Score: 0.158
-
Iniguez E, Schocker NS, Subramaniam K, Portillo S, Montoya AL, Al-Salem WS, Torres CL, Rodriguez F, Moreira OC, Acosta-Serrano A, Michael K, Almeida IC, Maldonado RA. An a-Gal-containing neoglycoprotein-based vaccine partially protects against murine cutaneous leishmaniasis caused by Leishmania major. PLoS Negl Trop Dis. 2017 Oct; 11(10):e0006039.
Score: 0.151